SOURCE: Spiracur Inc

Spiracur Inc

March 09, 2011 09:01 ET

Spiracur's SNaP Wound Care System Awarded American Podiatric Medical Association's Seal of Approval

SUNNYVALE, CA--(Marketwire - March 9, 2011) - Spiracur® Inc., the developer of an ultraportable and disposable negative pressure wound therapy (NPWT) device, today announced that it has been awarded the prestigious American Podiatric Medical Association's (APMA) Seal of Approval for its innovative SNaP® Wound Care System. APMA, the leading resource for foot and ankle health information, awarded the Seal to Spiracur's SNaP System for its contributions to better foot health and mobility.

"We are extremely honored to receive the coveted APMA Seal of Approval for our SNaP Wound Care System, and we are confident this award will help to further educate patients about the benefits of mechanically powered NPWT for the treatment of chronic wounds," said Gary Restani, president and CEO, Spiracur. "People suffering from chronic wounds can also experience a significant change in their quality of life. The SNaP System offers proven wound care treatment in a small and discreet device that easily fits under clothing, which enables patients to maintain their daily routine activities without exposing their wound care treatment. As a result, we believe treatment outcomes and quality of life are notably improved for a larger number of patients."

Spiracur's SNaP Wound Care System (Smart Negative Pressure) is changing the approach of how wound healing is delivered to patients. Its inventive design eliminates the electric or battery powered pump traditionally used to deliver NPWT. The SNaP System is completely silent and lightweight, weighing only 2.2 ounces.

"The SNaP Wound Care System has proven to be a vital treatment for wound care, especially for the millions of people battling complications from diabetes," said Dr. Kathleen Stone, president of APMA. "It has been thoroughly evaluated and found to be highly beneficial to foot health. For this reason it has been granted APMA's Seal of Approval."

Spiracur recently announced encouraging interim results from a clinical study highlighting the safety and efficacy of the SNaP System for the treatment of chronic lower extremity wounds, published in the March-April 2011 issue of Wound Repair and Regeneration. Interim analysis supports the efficacy and safety of the company's mechanically powered SNaP System and non-inferiority compared to the traditional electrically powered Vacuum-Assisted Closure (VAC®) System. Patient exit survey data were collected including Quality of Life (QOL) measurements. When patients were asked if they were able to work and perform normal daily activities while being treated with the NPWT device, 92.4 percent agreed that they could work and perform daily activities using the SNaP System compared to 33.3 percent of patients using the VAC System. When asked about sleep disruption, 100 percent of patients using the SNaP System said the device did not bother them while trying to go to sleep, yet 41.7 percent of patients using the VAC System felt that their sleep was disrupted by the device. By and large, the SNaP System interfered less with overall activity.

About APMA
Founded in 1912, APMA is headquartered in Bethesda, Maryland. Currently, the organization represents a vast majority of the estimated 15,000 podiatrists in the country. In addition to the national headquarters, APMA boasts 53 state component locations throughout the United States and its territories, as well as affiliated societies. APMA's Education Foundation, established in 1959, is dedicated to advancing the growth and stability of podiatric medicine throughout student scholarships and increasing nationwide awareness of foot and ankle health. For more information, visit

About Spiracur Inc.
Spiracur Inc., headquartered in Sunnyvale, Calif., is a privately held medical device company focused on the development of innovative wound healing technologies. Spiracur was founded out of the Stanford Biodesign Innovation Program in 2007. Its first product, the SNaP Wound Care System, is the result of patient and clinician feedback that current negative pressure wound therapies were too cumbersome. The SNaP Wound Care System was cleared by the U.S. Food & Drug Administration (FDA) in August 2009 in a new therapy category the FDA has defined as "non-powered" NPWT devices, and the company obtained CE Mark approval for the device in December 2010. The SNaP Wound Care System is indicated for patients who would benefit from a suction device for wound healing and further indicated for removal of small amounts of exudate (fluid) from chronic, acute, traumatic, subacute and dehisced wounds, as well as ulcers (such as diabetic or pressure), and surgically closed incisions. Spiracur strives to develop products that truly focus on patient care. For more information, please visit

SNaP, Spiracur and the Spiracur Design are registered trademarks of Spiracur Inc.

VAC is a registered trademark of Kinetic Concepts, Inc.

Contact Information